HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preoperative lamivudine therapy in HBV DNA positive recipients: is it always necessary?

AbstractBACKGROUND/AIMS:
Long-term preoperative lamivudine therapy has been recommended for patients with positive HBV DNA to suppress HBV replication before liver transplantation. However, it is unclear whether preoperative lamivudine therapy is mandatory in HBV DNA positive patients to reliably prevent HBV recurrence or whether transplantation should be delayed to allow time for sufficient preoperative lamivudine therapy.
METHODOLOGY:
From January 2000 to January 2004, thirty-eight patients serum positive for HBV DNA who survived more than 3 months after transplantation and received postoperative combination prophylaxis with hepatitis B immune globulin and lamivudine were enrolled.
RESULTS:
Total 2-year recurrence rate was 8.7%. When these 38 patients were divided into two groups according to preoperative lamivudine therapy duration: group 1 (n = 11) 4 weeks or more and group 2 (n = 27) less than 4 weeks, recurrences were detected in 3 (27.2%) and 4 (14.8%) patients in groups 1 and 2, respectively, i.e. a similar recurrence rate in both groups (p = 0.390). Moreover, in a subgroup of 20 patients who received preoperative lamivudine therapy for less than one week, only one (5%) experienced HBV recurrence.
CONCLUSIONS:
Our findings indicate that postoperative combination prophylaxis is effective and that preoperative lamivudine therapy is unlikely to be obligatory despite a positive preoperative serum HBV DNA status.
AuthorsHae Won Lee, Kyung-Suk Suh, Nam-Joon Yi, Sung Hoon Yang, Eung-Ho Cho, Jai Young Cho, Choon Hyuck Kwon, Yong Beom Cho, Kuhn Uk Lee
JournalHepato-gastroenterology (Hepatogastroenterology) Vol. 54 Issue 78 Pg. 1783-7 (Sep 2007) ISSN: 0172-6390 [Print] Greece
PMID18019718 (Publication Type: Journal Article)
Chemical References
  • DNA, Viral
  • Immunoglobulins
  • Immunosuppressive Agents
  • Lamivudine
Topics
  • Adult
  • DNA, Viral (blood, metabolism)
  • Female
  • Hepatitis B (drug therapy, immunology, virology)
  • Humans
  • Immunoglobulins (chemistry)
  • Immunosuppressive Agents
  • Lamivudine (therapeutic use)
  • Liver Transplantation (methods)
  • Male
  • Middle Aged
  • Models, Statistical
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: